Oncolytics Biotech reports accelerating enrollment in REO 033 Phase 2 trial for RAS-mutant MSS colorectal cancer
ONCY•Oncolytics Biotech reported accelerating enrollment in its randomized REO 033 Phase 2 study of second-line RAS-mutant, MSS metastatic colorectal cancer. An update is targeted for year-end 2026, with interim Part A results to be presented in the future.
1. Trial enrollment accelerates
Oncolytics Biotech reported accelerating enrollment in REO 033, which is testing whether adding pelareorep improves outcomes versus standard treatment in a controlled, head-to-head study. The company is targeting an update for year-end 2026; FDA alignment outlined a potential accelerated-approval route tied to tumor response, with confirmatory approval tied to longer-term disease control.
